These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21078752)

  • 1. New drugs for hyponatraemia.
    Amin A; Meeran K
    BMJ; 2010 Nov; 341():c6219. PubMed ID: 21078752
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan and hyponatremia in a patient with cirrhosis.
    Boyer TD
    Hepatology; 2010 Feb; 51(2):699-702. PubMed ID: 20101750
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecule of the Month: Conivaptan hydrochloride.
    Drug News Perspect; 2006 Nov; 19(9):574. PubMed ID: 17220962
    [No Abstract]   [Full Text] [Related]  

  • 5. The vaptans: just landed. But how was the trip?
    Gross P
    Nephrol Dial Transplant; 2010 May; 25(5):1367-8. PubMed ID: 20200008
    [No Abstract]   [Full Text] [Related]  

  • 6. The vaptans ante portas: a status report.
    Gross P; Marczewski T; Herbrig K
    Nephrol Dial Transplant; 2009 May; 24(5):1371-3. PubMed ID: 19218537
    [No Abstract]   [Full Text] [Related]  

  • 7. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
    Cassagnol M; Shogbon AO; Saad M
    J Pharm Pract; 2011 Aug; 24(4):391-9. PubMed ID: 21813818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan (Samsca) for hyponatremia.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):95-6. PubMed ID: 20224525
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
    Josiassen RC; Curtis J; Filmyer DM; Audino B; Skuban N; Shaughnessy RA
    Expert Opin Pharmacother; 2010 Mar; 11(4):637-48. PubMed ID: 20163274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of oral vasopressin V2 receptor antagonist for hyponatremia in acute brain injury.
    Jeon SB; Choi HA; Lesch C; Kim MC; Badjatia N; Claassen J; Mayer SA; Lee K
    Eur Neurol; 2013; 70(3-4):142-8. PubMed ID: 23887035
    [No Abstract]   [Full Text] [Related]  

  • 11. [Disorders of body water regulation and the therapy--vasopressin antagonists].
    Ishikawa S; Saito T
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1654-9. PubMed ID: 9410978
    [No Abstract]   [Full Text] [Related]  

  • 12. [Disorders of body water regulation and the therapy using diuretics].
    Orita Y; Nakahama H
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1660-4. PubMed ID: 9410979
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aquaretic drugs--a new therapeutic principle in treatment of hyponatremia?].
    Hensen J; Buchfelder M; Gross P
    Fortschr Med; 1997 Jun; 115(17):46-50. PubMed ID: 9312543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conivaptan (Vaprisol) for hyponatremia.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):51-2. PubMed ID: 16785851
    [No Abstract]   [Full Text] [Related]  

  • 15. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y; Sato O; Fujiki H
    Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract]   [Full Text] [Related]  

  • 16. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conivaptan Yamanouchi.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Massive aquaresis after tolvaptan administration and albumin infusion in a patient with alcoholic cirrhosis.
    Cho C; Logan JL; Lien YH
    Am J Med; 2012 Jan; 125(1):e5-6. PubMed ID: 22075044
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
    Chen S; Jalandhara N; Batlle D
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):82-95. PubMed ID: 17251996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.